EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds in this research cluster are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Research Cluster
Anti-Aging & Longevity Peptides
Anti-aging peptides sit in the research area where the distance between compelling preclinical data and actionable human evidence is largest—and where that distance is most consistently obscured in popular coverage. Several compounds in this cluster have generated genuine scientific excitement based on animal data or mechanistic plausibility. That excitement is worth reporting honestly. It is not the same as clinical evidence in humans.
This cluster spans thymic peptide bioregulators with decades of Russian clinical data, mitochondria-targeting compounds with Western Phase II trials, senolytics with striking mouse results and no human data, and observational evidence that certain endogenous peptides decline with age. Each of these is a different category of evidence. The tier system on this page is doing real work.
Cluster at a Glance
|
10 Compounds Covered |
1 FDA Approved |
4 Pilot Data |
2 Preclinical |
3 It’s Complicated |
|
Approved Drug FDA-approved or equivalent regulatory approval |
Pilot / Limited Human Data Small or preliminary human studies |
Preclinical Only Animal models and cell culture only |
It’s Complicated Mixed evidence or classification issues |
BLUF: Bottom Line Up Front
SS-31 is the only compound here with regulatory approval—FDA-approved for Barth syndrome in 2025. It is the measuring stick for this cluster. Below it, the evidence thins rapidly: three Khavinson bioregulators with single-source Russian clinical data, one senolytic (FOXO4-DRI) stuck in preclinical for eight years, two mitochondrial peptides with correlational but no interventional human data (Humanin, Glutathione), and two large proteins (GDF11, Klotho) whose biology is extraordinary but whose clinical translation is nonexistent. The gap between mechanistic excitement and actionable evidence defines this cluster.
In This Article
Compounds in This Cluster
All 10 compounds in the Anti-Aging & Longevity Peptides cluster, organized by mechanism and editorial function. Each grouping reflects how these compounds relate to each other scientifically—not just alphabetically.
Group 1 of 5
The Mitochondrial Protectors
SS-31 is the FDA-approved anchor of the cluster—a mitochondrial-targeted peptide with Phase III data. Humanin is an endogenous mitochondrial-derived peptide linked to centenarian longevity. Both address cellular energy decline, the core mechanism of aging.
Group 2 of 5
The Khavinson Bioregulators
Three compounds from the same Russian research tradition—Vladimir Khavinson’s bioregulation theory that short peptides extracted from specific organs regulate those organs’ function. All share a single-lab evidence concentration problem.
|
|
|
Group 3 of 5
The Senolytic Frontier
FOXO4-DRI is the only true senolytic peptide—designed to selectively destroy senescent cells. An elegant mechanism that has been stuck in preclinical for eight years.
|
Group 4 of 5
The Controversial Proteins
GDF11 and Klotho are large proteins—not peptides—with extraordinary biology and unresolved scientific disputes. GDF11 triggered one of the most dramatic reversal-of-findings episodes in recent biomedical research.
|
|
Group 5 of 5
The Antioxidant Tripeptide
Glutathione is the body’s master antioxidant—technically a tripeptide, widely available, and the subject of a growing longevity research literature.
|
How These Compounds Relate
The ten compounds in this cluster address longevity through four distinct biological axes. SS-31 and Humanin target mitochondrial function directly—the former via cardiolipin stabilization and ROS reduction, the latter as an endogenous mitochondrial-derived peptide with cytoprotective activity. NAD+ Peptide and Glutathione also address mitochondrial and oxidative pathways, making cellular energy and redox balance a recurring theme across four compounds. This convergence is not incidental: mitochondrial dysfunction is one of the most consistently cited hallmarks of aging in the scientific literature.
The Khavinson bioregulators (Epitalon, Pinealon, Thymalin) share a theoretical framework in which ultrashort peptides regulate organ-specific gene expression. They also share an evidence problem: decades of publications, almost entirely from one institutional network, with no independent Western replication. FOXO4-DRI represents the most mechanistically novel compound—a senolytic rather than a trophic or modulatory agent. Where most compounds here seek to support aging tissue, FOXO4-DRI seeks to selectively eliminate senescent cells that impair it.
A compound declining with age is not the same as a compound that extends lifespan when replaced. The step from “we measured less of this in old people” to “giving more of this extends healthy life in humans” remains unproven for most entries here. GDF11 and Klotho illustrate this gap most dramatically: extraordinary observational biology, zero clinical translation.
| Shared Mechanism | Compounds |
|
Mitochondrial Protection Stabilizing mitochondrial membranes, reducing oxidative damage, or enhancing cellular energy metabolism to counteract age-related decline. |
SS-31 (Elamipretide), Humanin, NAD+ Peptide, Glutathione |
|
Bioregulation / Gene Reactivation The Khavinson theory: ultrashort peptides interact with DNA promoter regions to reactivate genes silenced by aging in specific organ systems. |
Epitalon, Pinealon, Thymalin |
|
Senescent Cell Clearance Selectively triggering apoptosis in senescent cells that secrete pro-inflammatory factors and impair surrounding tissue. |
FOXO4-DRI |
|
Systemic Rejuvenation Signaling Large circulating proteins associated with youthful physiology in parabiosis and observational studies, but with no defined delivery mechanism. |
GDF11, Klotho |
Plain English
This cluster has one FDA-approved compound and nine others at various stages of “promising but unproven.” The four mitochondrial compounds address cellular energy—the engine of aging. The three Khavinson peptides come from a Russian program with real data but no Western validation. FOXO4-DRI wants to kill old cells instead of helping them. And GDF11 and Klotho are fascinating proteins that nobody knows how to turn into medicine yet.
Stay Current
New research, new articles, no noise
Peptidings publishes long-form peptide research articles grounded in primary literature. Subscribe to get new compound articles, cluster updates, and evidence reviews delivered to your inbox.
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.